-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News, March 18, March 17, NMPA official website showed that Puli Pharmaceutical's desloratadine dispersible tablets and desloratadine dry suspension passed the consistency evaluation
.
Deloratadine is a clinical first-line anti-allergic drug, and Prism Pharma's dispersible tablets and dry suspensions are exclusive dosage forms
.
According to data from Mi Nei.
com, the sales of terminal desloratadine in China's public medical institutions in 2019 were close to 600 million yuan
.
Desloratadine is a non-sedative long-acting tricyclic antihistamine and the active metabolite of loratadine.
It can selectively antagonize peripheral H1 receptors and inhibit various allergic inflammatory chemicals.
The release of the medium relieves the symptoms of allergic rhinitis or chronic idiopathic urticaria
.
According to data from Minai.
com, in 2019, the sales of terminal desloratadine in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) were close to 600 million yuan, and Puli Pharmaceuticals accounted for 78.
83%.
Market share
.
In terms of dosage form, the market share of tablets and solutions of this product totals over 90%
.
The brand pattern of the terminal desloratadine in China's public medical institutions in 2019.
Source: Meinenet.
com.
The terminal competition pattern of Chinese public medical institutions.
The current domestically listed desloratadine products include desloratadine tablets and desloratadine dispersible tablets.
, Desloratadine dry suspension, desloratadine capsules, desloratadine syrup and desloratadine oral solution
.
Except for desloratadine tablets and desloratadine syrup, other products are exclusive varieties
.
The oral constant-release dosage form of desloratadine has been included in the third batch of centralized procurement.
Two companies , Puli Pharmaceutical and Xinlitai, won the bid and divided the market
.
Up to now, 4 varieties of desloratadine in the market have been reviewed, including desloratadine tablets (Puli Pharmaceuticals, Xinlitai), desloratadine oral solution (Lon Nol Pharmaceuticals), and desloratadine Tadine Dispersible Tablets (Puli Pharmaceuticals) and desloratadine dry suspension (Puli Pharmaceuticals)
.
Source: Mi Nei Net database, NMPA
.
Deloratadine is a clinical first-line anti-allergic drug, and Prism Pharma's dispersible tablets and dry suspensions are exclusive dosage forms
.
According to data from Mi Nei.
com, the sales of terminal desloratadine in China's public medical institutions in 2019 were close to 600 million yuan
.
Desloratadine is a non-sedative long-acting tricyclic antihistamine and the active metabolite of loratadine.
It can selectively antagonize peripheral H1 receptors and inhibit various allergic inflammatory chemicals.
The release of the medium relieves the symptoms of allergic rhinitis or chronic idiopathic urticaria
.
According to data from Minai.
com, in 2019, the sales of terminal desloratadine in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) were close to 600 million yuan, and Puli Pharmaceuticals accounted for 78.
83%.
Market share
.
In terms of dosage form, the market share of tablets and solutions of this product totals over 90%
.
The brand pattern of the terminal desloratadine in China's public medical institutions in 2019.
Source: Meinenet.
com.
The terminal competition pattern of Chinese public medical institutions.
The current domestically listed desloratadine products include desloratadine tablets and desloratadine dispersible tablets.
, Desloratadine dry suspension, desloratadine capsules, desloratadine syrup and desloratadine oral solution
.
Except for desloratadine tablets and desloratadine syrup, other products are exclusive varieties
.
The oral constant-release dosage form of desloratadine has been included in the third batch of centralized procurement.
Two companies , Puli Pharmaceutical and Xinlitai, won the bid and divided the market
.
Up to now, 4 varieties of desloratadine in the market have been reviewed, including desloratadine tablets (Puli Pharmaceuticals, Xinlitai), desloratadine oral solution (Lon Nol Pharmaceuticals), and desloratadine Tadine Dispersible Tablets (Puli Pharmaceuticals) and desloratadine dry suspension (Puli Pharmaceuticals)
.
Source: Mi Nei Net database, NMPA
